Dr. Thomas A. Jandl, MD

Dr. Jandl practices at Stony Brook Internists in Stony Brook, New York.

Dr. Jandl's NPI, 1306265301, was assigned on April 8, 2014. Dr. Jandl graduated from Ludwig Maximilian University of Munich Faculty of Medicine in 2002. Dr. Jandl holds New York license 297959-1.

Dr. Jandl's primary practice is Stony Brook Internists, at 3 Edmund D Pellegrino Rd, Stony Brook, NY 11794 in Suffolk County. The practice phone is (631) 444-2448.

Dr. Jandl's primary practice is Stony Brook Internists in Stony Brook, New York. Dr. Jandl is also affiliated with Stony Brook University Hospital. The medical group on file is Stony Brook Internists.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Jandl practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Jandl's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Jandl is board certified in internal medicine by the American Board of Internal Medicine. Dr. Jandl is licensed in New York.

Dmand AI lists chronic anemia, chronic leukemia, deep vein thrombosis (DVT), immune deficiency disease, lymphoma and multiple myeloma among the conditions Dr. Jandl treats.

CMS data shows 532 Medicare services from Dr. Jandl across 8 procedure codes in 2024, for 160 Medicare patients. Medicare paid $63,584 for them.

CMS counts 160 Medicare patients who saw Dr. Jandl in 2024. The largest group is 75 to 84, with 64 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 20% are also on Medicaid. Their average risk score is 2.29, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Jandl's median patient age at 68, with 48% women.

In 2024, Dr. Jandl wrote 101 Medicare Part D claims for 24 patients. 91% of them were for generic drugs. CMS names the drug for 17 of them, across 1 drug with 11 or more claims each, at $442 in total drug cost. In 2023, CMS named 13 claims across 1 drug.

Dr. Jandl accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Jandl as offering telehealth.

Dmand AI links 11 papers to Dr. Jandl, published from 2012 to 2024. 2012 was the busiest year, with 2. The most frequent topics are Melanins, Mice, Inbred BALB C and Antibodies, Monoclonal. Dr. Jandl's most frequent co-authors are Betsy C. Herold, MD, Matthew Harris, MD and Kami Kim, MD.

Dmand AI links Dr. Jandl to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Lymphoma, Large B-Cell, Diffuse and Lymphoma, B-Cell.

CMS Open Payments shows 30 general payments to Dr. Jandl from 17 drug and device companies from 2019 to 2025. Food and beverage make up the largest share, 73% of the total. Astellas Pharma US Inc paid the most, $161.

Dr. Jandl graduated from Ludwig Maximilian University of Munich Faculty of Medicine in 2002.

Dr. Jandl is in network with 12 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.